Cancer‐testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis

Abstract Introduction Cancer testis (CT) antigens are attractive targets for cancer immunotherapy because of their expression restriction and immunogenicity. The acrosin binding protein (ACRBP) is a member of CT antigens. This study aimed to evaluate ACRBP expression and immunogenicity in ovarian ca...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lina Lin, Weixia Nong, Bin Luo, Yingying Ge, Xia Zeng, Feng Li, Rong Fan, Qingmei Zhang, Xiaoxun Xie
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	ACRBP cancer‑testis antigen diagnostic marker immunotherapy ovarian cancer Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/5d2c0dd73fbd4bcb99c51a4afd50e335
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5d2c0dd73fbd4bcb99c51a4afd50e335
record_format	dspace
spelling	oai:doaj.org-article:5d2c0dd73fbd4bcb99c51a4afd50e3352021-11-12T19:57:15ZCancer‐testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis2050-452710.1002/iid3.534https://doaj.org/article/5d2c0dd73fbd4bcb99c51a4afd50e3352021-12-01T00:00:00Zhttps://doi.org/10.1002/iid3.534https://doaj.org/toc/2050-4527Abstract Introduction Cancer testis (CT) antigens are attractive targets for cancer immunotherapy because of their expression restriction and immunogenicity. The acrosin binding protein (ACRBP) is a member of CT antigens. This study aimed to evaluate ACRBP expression and immunogenicity in ovarian cancer (OC). Methods The expression level of ACRBP in OC tissues, normal ovarian tissues, and cell lines was detected via quantitative real‐time polymerase chain reaction (qRT‐PCR) and immunohistochemistry. We determined the levels of ACRBP antigen and antibody in serum samples collected from patients with OC and healthy donors using enzyme‐linked immunosorbent assays (ELISA), the level of ACRBP in cell‐cultured medium was also tested. Results ACRBP mRNA and protein expressions were upregulated in OC tissues relative to normal tissue, especially highly expressed in epithelial ovarian cancer (EOC). Moreover, ACRBP expression was significantly correlated with International Federation of Gynecology and Obstetrics (FIGO) stage and chemosensitivity. Serological analysis showed that anti‐ACRBP antibody was detected in the sera of 16 of the 56 (28.5%) patients with OC but not in healthy donors. The area under the receiver operating characteristic curve for ACRBP antibody was 0.802 (95% confidence interval [CI]: 0.708–0.876), and the sensitivity and specificity for ACRBP antibody was 85.71% and 55.0%, respectively. Kaplan–Meier analysis revealed that the overall survival (OS) and disease‐free survival (DFS) in OC patients with high ACRBP expression were significantly lower than those with low expression (p = 0.040, p = 0.021). However, ACRBP antibody level was not associated with prognosis. Conclusion ACRBP expression was upregulated in OC tissues and induced humoral immune response in patients with OC, suggesting that ACRBP is a potential prognostic biomarker and a target of tumor immunotherapy for OC.Lina LinWeixia NongBin LuoYingying GeXia ZengFeng LiRong FanQingmei ZhangXiaoxun XieWileyarticleACRBPcancer‑testis antigendiagnostic markerimmunotherapyovarian cancerImmunologic diseases. AllergyRC581-607ENImmunity, Inflammation and Disease, Vol 9, Iss 4, Pp 1759-1770 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	ACRBP cancer‑testis antigen diagnostic marker immunotherapy ovarian cancer Immunologic diseases. Allergy RC581-607
spellingShingle	ACRBP cancer‑testis antigen diagnostic marker immunotherapy ovarian cancer Immunologic diseases. Allergy RC581-607 Lina Lin Weixia Nong Bin Luo Yingying Ge Xia Zeng Feng Li Rong Fan Qingmei Zhang Xiaoxun Xie Cancer‐testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis
description	Abstract Introduction Cancer testis (CT) antigens are attractive targets for cancer immunotherapy because of their expression restriction and immunogenicity. The acrosin binding protein (ACRBP) is a member of CT antigens. This study aimed to evaluate ACRBP expression and immunogenicity in ovarian cancer (OC). Methods The expression level of ACRBP in OC tissues, normal ovarian tissues, and cell lines was detected via quantitative real‐time polymerase chain reaction (qRT‐PCR) and immunohistochemistry. We determined the levels of ACRBP antigen and antibody in serum samples collected from patients with OC and healthy donors using enzyme‐linked immunosorbent assays (ELISA), the level of ACRBP in cell‐cultured medium was also tested. Results ACRBP mRNA and protein expressions were upregulated in OC tissues relative to normal tissue, especially highly expressed in epithelial ovarian cancer (EOC). Moreover, ACRBP expression was significantly correlated with International Federation of Gynecology and Obstetrics (FIGO) stage and chemosensitivity. Serological analysis showed that anti‐ACRBP antibody was detected in the sera of 16 of the 56 (28.5%) patients with OC but not in healthy donors. The area under the receiver operating characteristic curve for ACRBP antibody was 0.802 (95% confidence interval [CI]: 0.708–0.876), and the sensitivity and specificity for ACRBP antibody was 85.71% and 55.0%, respectively. Kaplan–Meier analysis revealed that the overall survival (OS) and disease‐free survival (DFS) in OC patients with high ACRBP expression were significantly lower than those with low expression (p = 0.040, p = 0.021). However, ACRBP antibody level was not associated with prognosis. Conclusion ACRBP expression was upregulated in OC tissues and induced humoral immune response in patients with OC, suggesting that ACRBP is a potential prognostic biomarker and a target of tumor immunotherapy for OC.
format	article
author	Lina Lin Weixia Nong Bin Luo Yingying Ge Xia Zeng Feng Li Rong Fan Qingmei Zhang Xiaoxun Xie
author_facet	Lina Lin Weixia Nong Bin Luo Yingying Ge Xia Zeng Feng Li Rong Fan Qingmei Zhang Xiaoxun Xie
author_sort	Lina Lin
title	Cancer‐testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis
title_short	Cancer‐testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis
title_full	Cancer‐testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis
title_fullStr	Cancer‐testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis
title_full_unstemmed	Cancer‐testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis
title_sort	cancer‐testis antigen acrbp expression and serum immunoreactivity in ovarian cancer: its association with prognosis
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/5d2c0dd73fbd4bcb99c51a4afd50e335
work_keys_str_mv	AT linalin cancertestisantigenacrbpexpressionandserumimmunoreactivityinovariancanceritsassociationwithprognosis AT weixianong cancertestisantigenacrbpexpressionandserumimmunoreactivityinovariancanceritsassociationwithprognosis AT binluo cancertestisantigenacrbpexpressionandserumimmunoreactivityinovariancanceritsassociationwithprognosis AT yingyingge cancertestisantigenacrbpexpressionandserumimmunoreactivityinovariancanceritsassociationwithprognosis AT xiazeng cancertestisantigenacrbpexpressionandserumimmunoreactivityinovariancanceritsassociationwithprognosis AT fengli cancertestisantigenacrbpexpressionandserumimmunoreactivityinovariancanceritsassociationwithprognosis AT rongfan cancertestisantigenacrbpexpressionandserumimmunoreactivityinovariancanceritsassociationwithprognosis AT qingmeizhang cancertestisantigenacrbpexpressionandserumimmunoreactivityinovariancanceritsassociationwithprognosis AT xiaoxunxie cancertestisantigenacrbpexpressionandserumimmunoreactivityinovariancanceritsassociationwithprognosis
_version_	1718430319368994816

Cancer‐testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis

Ejemplares similares